5'-Nitro-indirubinoxime, an indirubin derivative, suppresses metastatic ability of human head and neck cancer cells through the inhibition of Integrin β1/FAK/Akt signaling

Cancer Letters

Volumn 306, Issue 2, 2011, Pages 197-204

  Kim, Soo A ^a   Kwon, Seong Min ^c   Kim, Jung Ae ^b   Kang, Keon Wook ^c   Yoon, Jung Hoon ^c   Ahn, Sang Gun ^c  

^a Dongguk University   (South Korea)

^b Yeungnam University   (South Korea)

^c Chosun University   (South Korea)

Author keywords

5' Nitro indirubinoxime; Head and neck cancer; Integrin 1; Invasion; Metastasis

Indexed keywords

5 NITROINDIRUBINOXIME; BETA1 INTEGRIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GELATINASE A; GELATINASE B; INDIRUBIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CHICKEN; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FERTILIZATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; METASTASIS INHIBITION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD29; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLONY-FORMING UNITS ASSAY; FOCAL ADHESION KINASE 1; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; OXIMES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 79955469358     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.006     Document Type: Article

References (36)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2002, 55(2005):74-108.
2. Seiwert T.Y., Cohen E.E. State-of-the-art management of locally advanced head and neck cancer. Br. J. Cancer 2005, 92:1341-1348.
3. St John M.A., Abemayor E., Wong D.T. Recent new approaches to the treatment of head and neck cancer. Anticancer Drugs 2006, 17:365-375.
4. Chung C.H., Ely K., McGavran L., Varella-Garcia M., Parker J., Parker N., Jarrett C., Carter J., Murphy B.A., Netterville J., Burkey B.B., Sinard R., Cmelak A., Levy S., Yarbrough W.G., Slebos R.J., Hirsch F.R. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 2006, 24:4170-4176.
5. Brown D., Wang R., Russell P. Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines. Otolaryngal. Head Neck Surg. 2000, 122:75-83.
6. Kim S.A., Kim Y.C., Kim S.W., Lee S.H., Min J.J., Ahn S.G., Yoon J.H. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin. Cancer Res. 2007, 13:253-259.
7. Kim S.A., Kim S.W., Chang S., Yoon J.H., Ahn S.G. 5'-Nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells. Cancer Lett. 2009, 274:72-77.
8. Yoon J.H., Kim S.A., Kwon S.M., Park J.H., Park H.S., Kim Y.C., Yoon J.H., Ahn S.G. 5'-Nitro-indirubinoxime induces G1 cell cycle arrest and apoptosis in salivary gland adenocarcinoma cells through the inhibition of Notch-1 signaling. Biochim. Biophys. Acta 2010, 1800:352-358.
9. Kim E.J., Park W.H., Ahn S.G., Yoon J.H., Kim S.W., Kim S.A. 5'-Nitro-indirubinoxime inhibits inflammatory response in TNF-alpha stimulated human umbilical vein endothelial cells. Atherosclerosis 2010, 211:77-83.
10. Kim S.A., Park G.W., Kim S., Kim S.G., Kim S.W., Ahn S.G., Yoon J.H. Gene expression profiling in the KB oral squamous cell carcinoma treated with 5'-nitro-indirubinoxime. Korean J. Oral Maxillofac. Pathol. 2009, 30:53-60.
11. Ermakova S.P., Kang B.S., Choi B.Y., Choi H.S., Schuster T.F., Ma W.Y., Bode A.M., Dong Z. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006, 66:9260-9269.
12. Park J.H., Yoon J.H., Kim S.A., Ahn S.G., Yoon J.H. (-)-Epigallocatechin-3-gallate inhibits invasion and migration of salivary gland adenocarcinoma cells. Oncol. Rep. 2010, 23:585-590.
13. Kim J.A., Cho K.B., Kim M.R., Park B.C., Kim S.K., Lee M.Y., Kang K.W. Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells. Cancer Lett. 2008, 268:225-232.
14. Maschler S., Wirl G., Spring H., Bredow D.V., Sordat I., Beug H., Reichmann E. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 2005, 24:2032-2041.
15. van Nimwegen M.J., van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem. Pharmacol. 2007, 73:597-609.
16. Karroum A., Mirshahi P., Benabbou N., Faussat A.M., Soria J., Therwath A., Mirshahi M., Hatmi M. Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways. Cancer Lett. 2010, 28:242-251.
17. Viala E., Pouysségur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann. NY Acad. Sci. 2004, 1030:208-218.
18. Calderwood D.A. Integrin activation. J. Cell Sci. 2004, 117:657-666.
19. Böttger T., Maschek H., Lobo M., Gottwohl R.G., Brenner W., Junginger T. Prognostic value of immunohistochemical expression of beta-1 integrin in pancreatic carcinoma. Oncology 1999, 56:308-313.
20. Park C., Zhang H., Pallavicini M., Gray J.W., Baehner F., Park C.J., Bissell M.J. β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional culture and in vivo. Cancer Res. 2006, 66:1256-1535.
21. Brockbank E.C., Bridges J., Marshall C.J., Sahai E. Integrin β1 is required for the invasive behavior but not proliferation of squamous cell carcinoma cells in vivo. Br. J. Cancer 2005, 92:102-112.
22. Schipper J.H., Unger A., Jahnke K. E-cadherin as a functional marker of the differentiation and invasiveness of squamous cell carcinoma of the head and neck. Clin. Otolaryngol. 1994, 19:381-384.
23. Thomas G.J., Jones J., Speight P.M. Integrins and oral cancer. Oral Oncol. 1997, 33:381-388.
24. Disatnik M.H., Rando T.A. Integrin-mediated muscle cell spreading. The role of protein kinase c in outside-in and inside-out signaling and evidence of integrin cross-talk. J. Biol. Chem. 1999, 274:32486-32492.
25. Lee M., Lee H.J., Seo W.D., Park K.H., Lee Y.S. Sialylation of integrin beta1 is involved in radiation-induced adhesion and migration in human colon cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76:1528-1536.
26. Lesniak D., Xu Y., Deschenes J., Lai R., Thoms J., Murray D., Gosh S., Mackey J.R., Sabri S., Abdulkarim B. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 2009, 69:8620-8628.
27. Schneider J.G., Amend S.R., Weilbaecher K.N. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 2011, 48:54-65.
28. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 2008, 8:604-617.
29. Khalili P., Arakelian A., Chen G., Plunkett M.L., Beck I., Parry G.C., Doñate F., Shaw D.E., Mazar A.P., Rabbani S.A. A non-RGDbased integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 2006, 5:2271-2280.
30. Stokes A., Joutsa J., Ala-Aho R., Pitchers M., Pennington C.J., Martin C., Premachandra D.J., Okada Y., Peltonen J., Grénman R., James H.A., Edwards D.R., Kähäri V.M. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin. Cancer Res. 2010, 16:2022-2035.
31. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23:1011-1027.
32. Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., de Lanerolle P., Cheresh D.A. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 1997, 137:481-492.
33. Garavello W., Maggioni D., Nicolini G., Motta L., Tredici G., Gaini R. Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: an ex vivo study. Oncol. Rep. 2010, 24:1073-1078.
34. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: cell fate control and signal integration in development. Science 1999, 284:770-776.
35. Ohishi K., Katayama N., Shiku H., Varnum-Finney B., Bernstein I.D. Notch signaling in hematopoiesis. Semin. Cell Dev. Biol. 2003, 14:143-150.
36. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006, 66:2778-2784.